WO2001003688A3 - Treatment of cyclooxygenase-2 mediated disorders using conjugated fatty acid compounds - Google Patents

Treatment of cyclooxygenase-2 mediated disorders using conjugated fatty acid compounds Download PDF

Info

Publication number
WO2001003688A3
WO2001003688A3 PCT/US2000/040138 US0040138W WO0103688A3 WO 2001003688 A3 WO2001003688 A3 WO 2001003688A3 US 0040138 W US0040138 W US 0040138W WO 0103688 A3 WO0103688 A3 WO 0103688A3
Authority
WO
WIPO (PCT)
Prior art keywords
fatty acid
cyclooxygenase
treatment
process comprises
mediated disorders
Prior art date
Application number
PCT/US2000/040138
Other languages
French (fr)
Other versions
WO2001003688A2 (en
Inventor
Zaheer Abbas
Carol Koboldt
Original Assignee
Pharmacia Corp
Zaheer Abbas
Carol Koboldt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp, Zaheer Abbas, Carol Koboldt filed Critical Pharmacia Corp
Priority to JP2001508969A priority Critical patent/JP2003506324A/en
Priority to AU64027/00A priority patent/AU6402700A/en
Priority to EP00951029A priority patent/EP1231913A2/en
Publication of WO2001003688A2 publication Critical patent/WO2001003688A2/en
Publication of WO2001003688A3 publication Critical patent/WO2001003688A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/231—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/295—Iron group metal compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/30—Copper compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/315—Zinc compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y113/00—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13)
    • C12Y113/11—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13) with incorporation of two atoms of oxygen (1.13.11)

Abstract

This invention is directed to a process for the prevention or treatment of inflammation or other cyclooxygenase-2 mediated disorders. This process comprises administering a conjugated fatty acid to an organism in an amount effective to prevent or treat the cyclooxygenase-2 mediated disorder by inhibiting cyclooxygenase -2. In one embodiment, the process comprises administering a fatty acid compound having formula (I) or a pharmaceutically acceptable salt thereof, wherein R1 is hydrogen, hydrocarbyl, or substituted hydrocarbyl; m is from 6 to 11; and the sum of n and m is from 13 to 16. In another embodiment, the process comprises administering a fatty acid compound having formula (VI) or a pharmaceutically acceptable salt thereof, wherein R6 is hydrogen, hydrocarbyl, or substituted hydrocarbyl; R7 is -OH, -SO¿3?H, -SH, -NH2, -PO3H2, or halogen; v is from 7 to 11; and the sum of v and w is from 11 to 15. This invention is also directed to a process for preparing a fatty acid compound. The process comprises combining a ylide with an aldehyde.
PCT/US2000/040138 1999-07-09 2000-06-07 Treatment of cyclooxygenase-2 mediated disorders using conjugated fatty acid compounds WO2001003688A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2001508969A JP2003506324A (en) 1999-07-09 2000-06-07 Treatment of cyclooxygenase-2-mediated disorders using conjugated fatty acid compounds
AU64027/00A AU6402700A (en) 1999-07-09 2000-06-07 Treatment of cyclooxygenase-2 mediated disorders using conjugated fatty acid compounds
EP00951029A EP1231913A2 (en) 1999-07-09 2000-06-07 Treatment of cyclooxygenase-2 mediated disorders using conjugated fatty acid compounds

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14303199P 1999-07-09 1999-07-09
US60/143,031 1999-07-09

Publications (2)

Publication Number Publication Date
WO2001003688A2 WO2001003688A2 (en) 2001-01-18
WO2001003688A3 true WO2001003688A3 (en) 2002-06-20

Family

ID=22502304

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/040138 WO2001003688A2 (en) 1999-07-09 2000-06-07 Treatment of cyclooxygenase-2 mediated disorders using conjugated fatty acid compounds

Country Status (4)

Country Link
EP (1) EP1231913A2 (en)
JP (1) JP2003506324A (en)
AU (1) AU6402700A (en)
WO (1) WO2001003688A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2304906A1 (en) * 2000-04-07 2001-10-07 1411198 Ontario Limited 13-hode, a regulator of vascular biocompatibility and an inhibitor of cell hyperplasia
IL142537A0 (en) 2001-04-11 2002-03-10 Yeda Res & Dev Pharmaceutical compositions for the treatment of autoimmune diseases
JP2003155231A (en) * 2001-11-20 2003-05-27 Kikkoman Corp Medicine and antiallergic agent
US20050032892A1 (en) * 2003-08-07 2005-02-10 The Procter & Gamble Company Compositions, kits, and methods for treating gastrointestinal conditions
JP5198865B2 (en) * 2005-08-26 2013-05-15 カルピス株式会社 Muscle pain inhibitor
US20100055219A1 (en) * 2006-03-15 2010-03-04 Tropical Technology Center Ltd. Antiinflammatory agent
EP2444086A1 (en) * 2010-10-22 2012-04-25 Almirall, S.A. Combinations comprising DHODH inhibitors and COX inhibitors
JP2012111720A (en) * 2010-11-25 2012-06-14 Fuji Flavor Kk Method for producing 5-undecenoic acid
JP6347734B2 (en) * 2014-12-05 2018-06-27 株式会社佐藤園 Tea-derived cyclooxygenase-2 inhibitor
US10751314B2 (en) 2016-07-08 2020-08-25 Stepan Specialty Profducts, Llc Compositions comprising rumenic acid-rich conjugated linoleic acid for joint health
US20230067205A1 (en) * 2020-07-29 2023-03-02 Medterra Pharma Llc Cannabinoid compositions and methods of using for the treatment of non-eosinophilic inflammation and inflammatory disorders

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996038137A1 (en) * 1995-06-02 1996-12-05 Wisconsin Alumni Research Foundation Methods for maintaining or elevating the cd-4 or cd-8 cell levels comprising the administration of conjugated linoleic acid; a new process for the manufacture of conjugated linoleic acid using lactobacillus sp
WO1998017269A1 (en) * 1996-10-17 1998-04-30 Kappa Pharmaceuticals Limited Use of zinc salts of conjugated linoleic acids to treat skin disorders
WO1998019675A1 (en) * 1996-11-05 1998-05-14 Wisconsin Alumni Research Foundation Use of conjugated linoleic acid to enhance natural killer lymphocyte function
AU5286398A (en) * 1993-05-28 1998-05-14 Suntory Holdings Limited Prevention and improvement of medical symptoms caused by leucotriene B4
DE19718245C1 (en) * 1997-04-30 1998-07-30 Henkel Kgaa Synthetic tri:glyceride(s) useful as food additives
WO1999029317A1 (en) * 1997-12-12 1999-06-17 Purdue Research Foundation Methods and compositions for treating diabetes
EP0955047A2 (en) * 1998-04-10 1999-11-10 The George Washington University Use of conjugated linoleic acids to modify platelet function
WO2000009118A1 (en) * 1998-08-13 2000-02-24 The Wistar Institute Methods for reducing atherosclerotic plaques
US6077868A (en) * 1999-07-20 2000-06-20 Wisconsin Alumni Research Foundation Selective inhibition of cyclooxygenase-2
WO2000037040A1 (en) * 1998-12-22 2000-06-29 Unilever Plc Skin care compositions containing cis-9, trans-11 linoleic acid
WO2000067596A1 (en) * 1999-05-07 2000-11-16 Trustees Of Tufts College Immune stimulating dietary supplement and methods of use thereof
JP2000336029A (en) * 1999-05-28 2000-12-05 Rinoru Oil Mills Co Ltd Breast cancer-inhibiting agent containing conjugated linolenic acid as active ingredient
US6160141A (en) * 1997-02-18 2000-12-12 Seidel; Michael C. Synthesis of conjugated eicosadienoic acid
US20010018453A1 (en) * 1999-04-01 2001-08-30 Seidel Michael C. Suppression of carcinoma using high purity conjugated fatty acid

Patent Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5286398A (en) * 1993-05-28 1998-05-14 Suntory Holdings Limited Prevention and improvement of medical symptoms caused by leucotriene B4
WO1996038137A1 (en) * 1995-06-02 1996-12-05 Wisconsin Alumni Research Foundation Methods for maintaining or elevating the cd-4 or cd-8 cell levels comprising the administration of conjugated linoleic acid; a new process for the manufacture of conjugated linoleic acid using lactobacillus sp
WO1998017269A1 (en) * 1996-10-17 1998-04-30 Kappa Pharmaceuticals Limited Use of zinc salts of conjugated linoleic acids to treat skin disorders
WO1998019675A1 (en) * 1996-11-05 1998-05-14 Wisconsin Alumni Research Foundation Use of conjugated linoleic acid to enhance natural killer lymphocyte function
US6160141A (en) * 1997-02-18 2000-12-12 Seidel; Michael C. Synthesis of conjugated eicosadienoic acid
DE19718245C1 (en) * 1997-04-30 1998-07-30 Henkel Kgaa Synthetic tri:glyceride(s) useful as food additives
WO1999029317A1 (en) * 1997-12-12 1999-06-17 Purdue Research Foundation Methods and compositions for treating diabetes
EP0955047A2 (en) * 1998-04-10 1999-11-10 The George Washington University Use of conjugated linoleic acids to modify platelet function
WO2000009118A1 (en) * 1998-08-13 2000-02-24 The Wistar Institute Methods for reducing atherosclerotic plaques
WO2000037040A1 (en) * 1998-12-22 2000-06-29 Unilever Plc Skin care compositions containing cis-9, trans-11 linoleic acid
US20010018453A1 (en) * 1999-04-01 2001-08-30 Seidel Michael C. Suppression of carcinoma using high purity conjugated fatty acid
WO2000067596A1 (en) * 1999-05-07 2000-11-16 Trustees Of Tufts College Immune stimulating dietary supplement and methods of use thereof
JP2000336029A (en) * 1999-05-28 2000-12-05 Rinoru Oil Mills Co Ltd Breast cancer-inhibiting agent containing conjugated linolenic acid as active ingredient
US6077868A (en) * 1999-07-20 2000-06-20 Wisconsin Alumni Research Foundation Selective inhibition of cyclooxygenase-2

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 201, no. 1, 1994, pages 257 - 265, ISSN: 0006-291X *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1994, CHO YUNHI ET AL: "13-Hydroxyoctadecadienoic acid reverses epidermal hyperproliferation via selective inhibition of protein kinase C-beta activity.", XP002180830, Database accession no. PREV199497314576 *
DATABASE WPI Section Ch Week 199833, Derwent World Patents Index; Class B05, AN 1998-378157, XP002183159 *
DATABASE WPI Section Ch Week 200123, Derwent World Patents Index; Class B05, AN 2001-220514, XP002180831 *
TRUITT A ET AL: "ANTIPLATELET EFFECTS OF CONJUGATED LINOLEIC ACID ISOMERS", BIOCHIMICA ET BIOPHYSICA ACTA, AMSTERDAM, NL, vol. 1438, no. 2, 1999, pages 239 - 246, XP000852565, ISSN: 0006-3002 *
XI S ET AL: "13-hydroxyoctadecadienoic acid (13-hode) suppress skin epidermal hyperproliferation: Modulation of nuclear expression of activator protein-1 (AP-1).", FASEB JOURNAL, vol. 13, no. 7, 23 April 1999 (1999-04-23), Annual Meeting of the American Societies for Experimental Biology on Biochemistry and Molecular Biology 99;San Francisco, California, USA; May 16-20, 1999, pages A1448, XP001024976, ISSN: 0892-6638 *
ZIBOH VINCENT A: "The significance of polyunsaturated fatty acids in cutaneous biology.", LIPIDS, vol. 31, no. SUPPL., 1996, pages S249 - S253, XP001032545, ISSN: 0024-4201 *

Also Published As

Publication number Publication date
WO2001003688A2 (en) 2001-01-18
AU6402700A (en) 2001-01-30
EP1231913A2 (en) 2002-08-21
JP2003506324A (en) 2003-02-18

Similar Documents

Publication Publication Date Title
MA25809A1 (en) ARYLMETHYLAMINE DERIVATIVES FOR USE AS TRYPTASE INHIBITORS
ES2165969T3 (en) AROMATIC CONDENSED NITROGEN COMPOUNDS 5.5 ARIL-SUBSTITUTED AS ANTI-INFLAMMATORY AGENTS.
ATE375341T1 (en) THIADIAZOLYLPIPERAZINE DERIVATIVES SUITABLE FOR THE TREATMENT OR PREVENTION OF PAIN
IL152770A (en) Gabapentin analogues for use in the preparation of compositions for treating sleep disorders
KR970704429A (en) USE OF DROLOXIFENE FOR THE TREATMENT OF CARDIOVASCULAR DISEASES FOR THE TREATMENT OF CARDIOVASCULAR DISEASES
CA2370030A1 (en) Sodium channel blocker compositions and the use thereof
AU646230B2 (en) Pharmaceutical compositions and methods for treating the symptoms of overindulgence
ATE374029T1 (en) TREATING ALZHEIMER'S DISEASE BY INCREASE CYTIDINE LEVELS IN VIVO
CA2289717A1 (en) Novel therapy for constipation
CA2260145A1 (en) Use of l-acetylcarnitine, l-isovalerylcarnitine, l-propionylcarnitine for increasing the levels of igf-1
WO2001003688A3 (en) Treatment of cyclooxygenase-2 mediated disorders using conjugated fatty acid compounds
WO2004032845A3 (en) R-nsaid esters and their use
EP1251126A3 (en) Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation
WO2000023057A3 (en) Atypical antiphsychotic in combination with acetylcholinesterase inhibitor for improving cognition
CA2283399A1 (en) Pyridazinones as inhibitors of cyclooxygenase-2
GR3031917T3 (en) Treatment of diseases caused by sebaceous gland disorders with acyl CoA cholesterol acyl transferase inhibitors
EA199900542A1 (en) COMPOUNDS OF SULPHONIC ACID OR SULPHONYLAMINO-N- (HETEROARALKYL) -ASAGHETHROCYCLOSYME
WO2001081332A3 (en) 2-fluorobenzenesulfonyl compounds for the treatment of inflammation
WO2003000173A3 (en) Use of branched-chain fatty acids and derivatives thereof for the treatment of pain
BR9608413A (en) Cerebral edema inhibitor
CA2282279A1 (en) Atropisomers of 3-heteroaryl-4(3h)-quinazolinones for the treatment of neurodegenerative and cns-trauma related conditions
CA2289017A1 (en) The use of a nitroxide or a prodrug thereof in the prophylactic and therapeutic treatment of cancer
DE69206607D1 (en) TREATMENT OF COGNITIVE DISORDERS.
WO2002058680A3 (en) Use of bicylic amino acids for preventing and treating visceral pain and gastrointestinal disorders
WO2001030334A3 (en) 6-methoxy-2-naphthylacetic acid prodrugs compositions for treating inflammation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2000951029

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWP Wipo information: published in national office

Ref document number: 2000951029

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2000951029

Country of ref document: EP